Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Dec;40(12):2824–2828. doi: 10.1128/aac.40.12.2824

Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects.

O Kozawa 1, T Uematsu 1, H Matsuno 1, M Niwa 1, S Nagashima 1, M Kanamaru 1
PMCID: PMC163630  PMID: 9124849

Abstract

Comparative pharmacokinetics and tolerability were studied in healthy elderly volunteers for two new fluoroquinolones, balofloxacin (Q-35) and grepafloxacin (OPC-17116), the main excretion routes being the renal and hepatic routes, respectively. Both agents were well tolerated in elderly subjects. In comparison with previously reported data from healthy younger adults, the absorption of balofloxacin was slightly delayed and urinary excretion was delayed and diminished. As a significant linear correlation was observed between renal clearance of balofloxacin and creatinine clearance, the delayed and diminished urinary recovery was attributed to the reduced renal function of the elderly subjects enrolled in the study. The absorption of grepafloxacin was also delayed, and the maximum plasma drug concentration and area under the plasma drug concentration-time curve were increased in the elderly by 31 and 48%, respectively, over those in younger adults on the basis of dose normalized to body weight. The plasma terminal elimination half-life and urinary recovery remained unchanged. Decreases in distribution volume and total body clearance in the elderly were considered to be the primary factors contributing to these differences.

Full Text

The Full Text of this article is available as a PDF (209.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ball A. P., Fox C., Ball M. E., Brown I. R., Willis J. V. Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients. J Antimicrob Chemother. 1986 May;17(5):629–635. doi: 10.1093/jac/17.5.629. [DOI] [PubMed] [Google Scholar]
  2. Blum M. D., Graham D. J., McCloskey C. A. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis. 1994 Jun;18(6):946–950. doi: 10.1093/clinids/18.6.946. [DOI] [PubMed] [Google Scholar]
  3. Bruno R., Iliadis M. C., Lacarelle B., Cosson V., Mandema J. W., Le Roux Y., Montay G., Durand A., Ballereau M., Alasia M. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients. J Pharmacokinet Biopharm. 1992 Dec;20(6):653–669. doi: 10.1007/BF01064424. [DOI] [PubMed] [Google Scholar]
  4. Chambers S. T. Quinolones. N Z Med J. 1995 Jul 14;108(1003):273–277. [PubMed] [Google Scholar]
  5. Child J., Andrews J. M., Wise R. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Antimicrob Agents Chemother. 1995 Feb;39(2):513–515. doi: 10.1128/aac.39.2.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Crome P., Flanagan R. J. Pharmacokinetic studies in elderly people. Are they necessary? Clin Pharmacokinet. 1994 Apr;26(4):243–247. doi: 10.2165/00003088-199426040-00001. [DOI] [PubMed] [Google Scholar]
  7. Davey P., McDonald T. Postmarketing surveillance of quinolones, 1990 to 1992. Drugs. 1993;45 (Suppl 3):46–53. doi: 10.2165/00003495-199300453-00010. [DOI] [PubMed] [Google Scholar]
  8. Iber F. L., Murphy P. A., Connor E. S. Age-related changes in the gastrointestinal system. Effects on drug therapy. Drugs Aging. 1994 Jul;5(1):34–48. doi: 10.2165/00002512-199405010-00004. [DOI] [PubMed] [Google Scholar]
  9. Imada T., Miyazaki S., Nishida M., Yamaguchi K., Goto S. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrob Agents Chemother. 1992 Mar;36(3):573–579. doi: 10.1128/aac.36.3.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ito T., Otsuki M., Nishino T. In vitro antibacterial activity of Q-35, a new fluoroquinolone. Antimicrob Agents Chemother. 1992 Aug;36(8):1708–1714. doi: 10.1128/aac.36.8.1708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Iwasaki H., Miyazaki S., Tsuji A., Yamaguchi K., Goto S. In vitro and in vivo antibacterial activities of Q-35, a novel fluoroquinolone. Chemotherapy. 1995 Mar-Apr;41(2):100–112. doi: 10.1159/000239330. [DOI] [PubMed] [Google Scholar]
  12. LeBel M., Barbeau G., Bergeron M. G., Roy D., Vallée F. Pharmacokinetics of ciprofloxacin in elderly subjects. Pharmacotherapy. 1986 Mar-Apr;6(2):87–91. doi: 10.1002/j.1875-9114.1986.tb03458.x. [DOI] [PubMed] [Google Scholar]
  13. Norrby S. R., Lietman P. S. Safety and tolerability of fluoroquinolones. Drugs. 1993;45 (Suppl 3):59–64. doi: 10.2165/00003495-199300453-00012. [DOI] [PubMed] [Google Scholar]
  14. Piddock L. J. New quinolones and gram-positive bacteria. Antimicrob Agents Chemother. 1994 Feb;38(2):163–169. doi: 10.1128/aac.38.2.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Regazzi M. B., Rondanelli R., Calvi M. The need for pharmacokinetics protocols in special cases. Pharmacol Res. 1993 Jan-Feb;27(1):21–31. doi: 10.1006/phrs.1993.1002. [DOI] [PubMed] [Google Scholar]
  16. Salom I. L., Davis K. Prescribing for older patients: how to avoid toxic drug reactions. Geriatrics. 1995 Oct;50(10):37-40, 43; discussion 44-5. [PubMed] [Google Scholar]
  17. Shah A., Lettieri J., Nix D., Wilton J., Heller A. H. Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects. Antimicrob Agents Chemother. 1995 Apr;39(4):1003–1006. doi: 10.1128/aac.39.4.1003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sloan R. W. Principles of drug therapy in geriatric patients. Am Fam Physician. 1992 Jun;45(6):2709–2718. [PubMed] [Google Scholar]
  19. Uematsu T., Nakashima M. Pharmacokinetic aspects of newer quinolones. Prog Drug Res. 1992;38:39–55. [PubMed] [Google Scholar]
  20. Uematsu T., Ohsawa Y., Mizuno A., Nakashima M. Analysis of a new fluoroquinolone derivative (Q-35) in human scalp hair as an index of drug exposure and as a time marker in hair. Int J Legal Med. 1994;106(5):237–243. doi: 10.1007/BF01225412. [DOI] [PubMed] [Google Scholar]
  21. Wakebe H., Mitsuhashi S. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria. Antimicrob Agents Chemother. 1992 Oct;36(10):2185–2191. doi: 10.1128/aac.36.10.2185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Walker J., Wynne H. Review: the frequency and severity of adverse drug reactions in elderly people. Age Ageing. 1994 May;23(3):255–259. doi: 10.1093/ageing/23.3.255. [DOI] [PubMed] [Google Scholar]
  23. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn. 1981 Nov;4(11):879–885. doi: 10.1248/bpb1978.4.879. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES